bivalirudin · Sandoz · NDA 020873
Angiomax
Earliest generic entry, as listed
27 Jan 2029
Blocked by patent: US 7582727, US 7598343.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 7582727 | — | 27 Jan 2029 |
| US 7598343 | — | 27 Jan 2029 |
| US 7582727 | product | 27 Jul 2028 |
| US 7598343 | product | 27 Jul 2028 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 020873 · 001 · RLD | injectable, intravenous | 250MG/VIAL | 27 Jan 2029 |